CytomX Therapeutics, Inc. (CTMX) jumped 94.55 percent to $1.78 in Monday trading after the company announced promising interim Phase 1 results for its EpCAM-targeting PROBODY ADC, CX-2051, in advanced colorectal cancer. The data demonstrated durable anti-tumor activity and tolerability in late-line metastatic CRC, an area with high unmet medical need.
The stock opened at $1.90 and traded between $1.65 and $2.18, a new 52-week high on the Nasdaq. Volume spiked to 90.9 million shares, far above its average of 2.4 million. CTMX previously closed at $0.93.
The results underscore the potential of CytomX's PROBODY technology to overcome long-standing challenges in targeting EpCAM, generating renewed investor enthusiasm.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.